Bioethics Unit, Istituto Superiore di Sanità, 00161 Rome, Italy.
Centre for Research Ethics & Bioethics (CRB), University of Uppsala, 751 05 Uppsala, Sweden.
Int J Environ Res Public Health. 2018 Sep 21;15(10):2072. doi: 10.3390/ijerph15102072.
The time required to reach a correct diagnosis is a key concern for rare disease (RD) patients. Diagnostic delay can be intolerably long, often described as an "odyssey" and, for some, a diagnosis may remain frustratingly elusive. The International Rare Disease Research Consortium proposed, as ultimate goal for 2017⁻2027, to enable all people with a suspected RD to be diagnosed within one year of presentation, if the disorder is known. Subsequently, unsolved cases would enter a globally coordinated diagnostic and research pipeline. In-depth analysis of the genotype through next generation sequencing, together with a standardized in-depth phenotype description and sophisticated high-throughput approaches, have been applied as diagnostic tools to increase the chance of a timely and accurate diagnosis. The success of this approach is evident in the Orphanet database. From 2010 to March 2017 over 600 new RDs and roughly 3600 linked genes have been described and identified. However, combination of -omics and phenotype data, as well as international sharing of this information, has raised ethical concerns. Values to be assessed include not only patient autonomy but also family implications, beneficence, non-maleficence, justice, solidarity and reciprocity, which must be respected and promoted and, at the same time, balanced among each other. In this work we suggest that, to maximize patients' involvement in the search for a diagnosis and identification of new causative genes, undiagnosed patients should have the possibility to: (1) actively participate in the description of their phenotype; (2) choose the level of visibility of their profile in matchmaking databases; (3) express their preferences regarding return of new findings, in particular which level of Variant of Unknown Significance (VUS) significance should be considered relevant to them. The quality of the relationship between individual patients and physicians, and between the patient community and the scientific community, is critically important for optimizing the use of available data and enabling international collaboration in order to provide a diagnosis, and the attached support, to unsolved cases. The contribution of patients to collecting and coding data comprehensively is critical for efficient use of data downstream of data collection.
获得正确诊断所需的时间是罕见病(RD)患者关注的关键问题。诊断延迟可能会非常漫长,通常被描述为“一段痛苦的历程”,对于某些人来说,可能会令人沮丧地无法确诊。国际罕见病研究联合会提出,作为 2017-2027 年的最终目标,使所有疑似 RD 患者在出现症状后一年内得到诊断,如果该疾病已知的话。随后,未解决的病例将进入全球协调的诊断和研究渠道。通过下一代测序对基因型进行深入分析,结合标准化的深入表型描述和复杂的高通量方法,已被用作诊断工具,以提高及时准确诊断的机会。这种方法的成功在 Orphanet 数据库中显而易见。从 2010 年到 2017 年 3 月,已经描述和确定了 600 多种新的 RD 和大约 3600 种相关基因。然而,-omics 和表型数据的组合以及这些信息的国际共享引发了伦理问题。需要评估的价值观不仅包括患者自主权,还包括家庭影响、惠益、不伤害、正义、团结和互惠,这些价值观必须得到尊重和促进,同时在彼此之间保持平衡。在这项工作中,我们建议,为了最大限度地提高患者在寻找诊断和鉴定新致病基因方面的参与度,未确诊的患者应该有以下可能性:(1)积极参与描述其表型;(2)选择其个人资料在匹配数据库中的可见度级别;(3)表达他们对新发现返回的偏好,特别是应将何种水平的意义不明的变异(VUS)视为与他们相关。个体患者与医生之间以及患者社区与科学界之间的关系质量对于优化可用数据的使用以及促进国际合作以提供诊断以及为未解决的病例提供支持至关重要。患者对全面收集和编码数据的贡献对于下游数据收集后的数据高效利用至关重要。
Int J Environ Res Public Health. 2018-9-21
Int J Environ Res Public Health. 2018-8-14
Hum Mutat. 2022-6
Orphanet J Rare Dis. 2024-1-27
Adv Exp Med Biol. 2017
Am J Hum Genet. 2017-5-4
Annu Rev Genomics Hum Genet. 2020-8-31
Orphanet J Rare Dis. 2023-11-9
Int J Environ Res Public Health. 2023-3-4
Front Psychol. 2023-1-19
Nat Genet. 2018-4
Adv Exp Med Biol. 2017
Ann Clin Transl Neurol. 2017-4-26
Am J Hum Genet. 2017-5-4
Orphanet J Rare Dis. 2017-5-3
Orphanet J Rare Dis. 2017-4-11